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ABSTRACT
Objective: To study the relationship between body
mass index (BMI) and mortality among 75-year-olds
with and without diabetes mellitus type 2 (DM) or
impaired fasting glucose (IFG).
Design: Prospective population-based cohort study
with a 10-year follow-up.
Participants: A random sample of 618 of the 1100
inhabitantsbornin1922andlivinginthecityofVa ¨stera ˚s
in 1997 were invited to participate in a cardiovascular
healthsurvey;70%ofthoseinvitedagreedtoparticipate
(432 individuals: 210 men, 222 women).
Outcome measures: All-cause and cardiovascular
mortality.
Results: 163 of 432 (38%) participants died during the
10-year follow-up period. The prevalence of DM or IFG
was 41% (35% among survivors, 48% among non-
survivors). The prevalence of obesity/overweight/
normal weight/underweight according to WHO
deﬁnitions was 12/45/42/1% (14/43/42/1% among
survivors, 9/47/42/2% among non-survivors). The
hazard rate for death decreased by 10% for every
kg/m
2 increase in BMI in individuals with DM/IFG (HR
0.91, 95% CI 0.86 to 0.97; p¼0.003). After adjustment
for sex, current smoking, diagnosed hypertension,
diagnosed angina pectoris, previous myocardial
infarction and previous stroke/transient ischaemic
attack, the corresponding decrease in mortality was
9% (HR 0.92, 95% CI 0.86 to 0.99; p¼0.017). These
ﬁndings remained after exclusion of individuals with
BMI<20 or those who died within 2-year follow-up. In
individuals without DM/IFG, BMI had no effect on
mortality (HR 1.01, 95% CI 0.95 to 1.07; p¼0.811).
The HR for BMI differed signiﬁcantly between
individuals with and without DM/IFG (p
interaction¼0.025). The increased all-cause mortality
in individuals with DM/IFG in combination with lower
BMI was driven by cardiovascular death.
Conclusion: High all-cause and cardiovascular
mortalitywasassociatedwithlowerBMIin75-year-olds
with DM/IFG but not in those without DM/IFG. Further
studies on the combined effect of obesity/overweight
and DM/IFG are needed in order to assess the
appropriateness of current guideline recommendations
for weight reduction in older people with DM/IFG.
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ARTICLE SUMMARY
Article focus
- To explore the combined effect of hypergly-
caemia and body mass index (BMI) on all-cause
and cardiovascular mortality in the elderly.
Key messages
- There was a signiﬁcant inverse relationship in
75-year-olds with type 2 diabetes mellitus (DM)
or impaired fasting glucose (IFG) between BMI
and rate of all-cause and cardiovascular
mortality.
- An obesity paradox or reverse epidemiology was
found in 75-year-olds with DM or IFG.
- Further studies on the combined effect of obesity/
overweight and DM/IFG are needed in order to
assess current guidelines for weight reduction in
older people with DM/IFG.
Strengths and limitations of this study
- Restricting our investigation to one age group
enabled us to omit age as a confounding factor,
allowing meaningful estimation of the relation-
ship between all-cause and cardiovascular
mortality and BMI in individuals with and
without hyperglycaemia, despite the relatively
small number of study participants. Furthermore,
because of the high participation rate, the
participants are more representative of the
population in a deﬁned geographical area than
described in most other studies on this topic.
These advantages are, however, offset by
difﬁculty in generalising our ﬁndings to those in
other age groups and from other geographical
areas. Nevertheless, it seems likely that our
results are applicable to Northern Europeans and
white North Americans in their seventies.
- A further limitation of the study is the fact that
mortality among invited individuals who did
not participate in the study (30%) was consid-
erably higher than among those who participated
(70%), mainly reﬂecting a higher prevalence
of diseases under treatment among non-
participants.
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Open Access ResearchINTRODUCTION
Obesity and overweight are well-known risk factors for
increased mortality. Thus, a large collaborative analysis
1
of baseline body mass index (BMI) versus overall
mortality in 57 prospective studies with 894576 partici-
pants (mean (SD) recruitment age 46 (11) years)
provides overwhelming evidence that overweight and
obesity, as reﬂected by BMI, are strong predictors of
all-cause mortality in the general population. This excess
mortality is mainly driven by an excess of cardiovascular
death.
Similarly, observational studies indicate that diabetes
mellitus type 2 (DM) and impaired fasting glucose
(IFG) play an important role in atherosclerotic cardio-
vascular morbidity and mortality as well as in all-cause
mortality.
2e6 IFG refers to a condition in which fasting
glucose levels are elevated above normal values but are
not high enough to be classiﬁed as diabetes mellitus.
7
IFG is a prediabetic state
8 and a risk factor for cardio-
vascular and all-cause mortality.
9 DM and IFG are
causeddor at least aggravateddby obesity.
5
The association between obesity and mortality
weakens
10e12 among the elderly and even disappears
13 14
among individuals above 80 years of age. Among elderly
($65 years) non-institutionalised relatively healthy
adults, Heiat et al
15 found a U-shaped relationship
between BMI and both all-cause and cardiovascular
mortality with a long ﬂat region between BMI 20 and
BMI 31. Similarly, the hazard ratio for the mortality rate
between diabetic compared with non-diabetic subjects
decreases among the elderly.
16 17
In certain chronic diseases, especially among older
people, an ‘obesity paradox’ or reversed epidemiology
has been observed
18e22 implying a paradoxically
decreased mortality and morbidity in association with
increasing BMI up to and including obesity. Better
survival among overweight/obese individuals is ‘para-
doxical’ from a primary prevention perspective in view of
the large body of evidence that obesity confers an
increased mortality risk.
1 To our knowledge, the obesity
paradox has not been reported among individuals with
DM/IFG.
The purpose of this study is to explore the combined
effect of BMI and DM/IFG on survival among 75-year-
olds. The examined cohort, comprising both men
and women, was randomly selected from the general
population.
METHODS
Study population
The city of Va ¨stera ˚s (130000 inhabitants) in central
Sweden has a population considered socioeconomically
representative of Sweden. In 1997 a random sample of
618 of the 1100 inhabitants born in 1922 (ie, 75 years
old) were invited to take part in a cardiovascular health
survey and 432 agreed to participate (70% of
those invited; 222 women, 210 men). Reasons for non-
participation of those invited were unknown (n¼46),
never reached (n¼29), died before examination (n¼2),
language or logistical problems (n¼27), locomotive
impairment (n¼28) or unwilling due to diseases under
treatment (n¼54).
The study was approved by the research ethics
committee of Uppsala University, Sweden and was
conducted in accordance with the Declaration of
Helsinki. All study subjects gave their informed consent.
Baseline examination
Recorded information included history of cardiovascular
and/or pulmonary diseases, hypertension, diabetes
mellitus, ongoing medication, height, weight, waist
circumference, heart rate, blood pressure and lifestyle
habits such as self-reported smoking.
Venous blood was sampled in the morning with the
subjects in a fasting state ($12 h). The blood glucose
samples were treated with a haemolytic reagent (Merck
Diagnostica, Darmstadt, Germany) and glucose was
determined enzymatically with glucose dehydrogenase
using a Cobas Mira analyser (Roche Diagnostics,
Rotkreuz, Switzerland). Fasting plasma glucose (FPG)
was determined from venous whole blood glucose using
the formula: FPG¼0.558+1.1193whole blood fasting
glucose.
23
Known diabetes was deﬁned as self-reported physician-
diagnosed diabetes (conﬁrmed from medical records by
PH, one of the authors). Seven patients with known
diabetes were on insulin treatment and 20 patients were
on oral glucose lowering drug treatment. Newly detected
diabetes was deﬁned as FPG $7.0 mmol/l
24 without
previously known diabetes. According to the WHO
recommendations,
7 diabetes can be diagnosed for
epidemiological purposes on the basis of only one
fasting blood glucose value. IFG was deﬁned according
to WHO recommendations
24 as FPG $6.1 mmol/l and
<7.0 mmol/l without previously known diabetes.
BMI was calculated as weight in kilograms divided by
the square of height in metres. BMI categories were
deﬁned according to the WHO recommendations
25
(underweight <18.5, normal weight 18.5e24.9, over-
weight 25.0e29.9, obesity $30.0). Waist circumference
was measured in the horizontal plane at the midpoint
between the lowest rib and the iliac crest.
Information on previous myocardial infarction and
stroke/transient ischaemic attack (TIA) was based on
self-reported case history and veriﬁed by medical
records. Hypertension was deﬁned by self-reported
physician-diagnosed high blood pressure in combination
with regular blood pressure lowering treatment.
Smoking status was classiﬁed as non-smoker, former
smoker or current smoker.
Prospective follow-up
All-cause mortality served as the primary end-point. The
study cohort was followed from the index examination in
1997 until 31 December 2007 or to the ﬁrst primary end-
point, resulting in a median follow-up of 10.6 years. Dates
and reasons for death were obtained from the Swedish
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Survival of the fattestpopulation register and the Swedish National Cause of
Death register. No participants were lost to follow-up.
The registers were linked to the study participants via
the unique personal identiﬁcation number allocated to
all Swedish citizens. The 10th revision of the Interna-
tional Statistical Classiﬁcation of Diseases (ICD) was used
to identify primary causes of death. For the present
analyses, causes of death were grouped into two
categories: cardiovascular (ICD-10: I 00eI 99) or non-
cardiovascular comprising all other causes of death
(conﬁrmed by PH, one of the authors). The study was
not powered to analyse more speciﬁc causes of death.
Statistical analysis
Continuous variables were summarised by means and SD
or, in the case of skewed distributions, by medians and
IQR. Categorical variables were summarised by numbers
and proportions. The Student t test and Wilcoxon
ManneWhitney’s rank sum test were used to compare
continuous variables. In case of skewly distributed vari-
ables only the p value for the Wilcoxon ManneWhitney’s
rank sum test is given. Categorical variables were
compared using Fisher’s exact test. The association
between BMI and waist circumference was assessed using
Pearson’s correlation coefﬁcient.
Crude and adjusted prospective associations between
BMI, FPG and all-cause mortality were assessed by HRs
and corresponding 95% CIs using uni- and multivariable
Cox proportional hazards regression (PHREG) models.
The interaction between BMI and FPG was explored by
introducing the interaction term of these variables into
a Cox PHREG model. For continuous variables, the
assumption of proportional hazards was assessed by
examining their interaction with time to death in the
Cox PHREG models. The proportional hazard assump-
tion for categorical variables was assessed by visual
inspection of the log( log(cumulative survival)).
Cumulative survival was estimated by means of the
KaplaneMeier method.
A two-sided p value <0.05 was regarded as statistically
signiﬁcant in all analyses. SPSS v 15.0 was used.
RESULTS
During a median follow-up of 10.6 years (range
0.2e11.0 years), 163 individuals (38%) died (98 men
and 65 women). The total number of person-years with
follow-up was 3918, implying 4.2 deaths per 100 person-
years at risk (men 5.5, women 3.1). Overall, 77 deaths
were from cardiovascular causes and 81 were non-
cardiovascular deaths (including 40 attributed to malig-
nancy). The cause of death was unknown in ﬁve cases.
Mortality among the 30% of invited individuals who did
not participate in the study was considerably higher
(67%) than among participants.
The baseline characteristics of participants are shown
in table 1. No unexpected differences between survivors
and non-survivors were found. There was a strong
correlation between BMI and waist circumference (men
r¼0.82, p<0.001; women r¼0.86, p<0.001), suggesting
that BMI strongly reﬂects abdominal obesity.
The results of the Cox PHREG analyses of the associ-
ation between BMI and all-cause mortality across DM/
IFG status are shown in table 2. Signiﬁcantly better
survival was found by increasing BMI in individuals with
Table 1 Baseline characteristics of the study cohort according to survival status
All participants
(n[432)
Survivors
(n[269)
Non-survivors
(n[163)
p Value (survivors
vs non-survivors)
Women 222 (51) 157 (58) 65 (40) <0.001
Known DM 34 (8) 16 (6) 18 (11) 0.066
Known or newly detected DM 80 (19) 42 (16) 38 (23) 0.055
DM or IFG 172 (40) 94 (35) 78 (48) 0.009
BMI category
Underweight 6 (1) 3 (1) 3 (2) NS*
Normal weight 181 (42) 112 (42) 69 (42) NS
Overweight 193 (45) 117 (43) 76 (47) NS
Obesity 52 (12) 37 (14) 15 (9) NS
Current smoker 45 (10) 21 (8) 24 (15) 0.034
Known hypertension 122 (28) 62 (23) 60 (37) 0.002
Angina pectoris 57 (13) 24 (9) 33 (20) 0.001
Previous myocardial infarction 41 (9) 14 (5) 27 (17) <0.001
Previous stroke or TIA 11 (3) 7 (3) 4 (2) NS
BMI (kg/m
2), mean (SD) 25.8 (3.6) 26.0 (3.7) 25.5 (3.4) NS
FPG (mmol/l), median (IQR)y 5.9 (5.5e6.5) 5.8 (5.4e6.4) 6.0 (5.5e6.8) 0.006
Waist (cm) women, mean (SD)z 88 (11) 88 (11) 89 (11) NS
Waist (cm) men, mean (SD)x 95 (8) 94 (9) 95 (8) NS
Values are number (%) unless otherwise stated.
*NS (non-signiﬁcant) denotes a p value >0.20.
yTo convert values for FPG to mg/dl, multiply by 18.01.
zValues missing in 18 individuals (11 survivors, 7 non-survivors).
xValues missing in 12 individuals (5 survivors, 7 non-survivors).
BMI, body mass index; DM, diabetes mellitus type 2; FPG, fasting plasma glucose; IFG, impaired fasting glucose; TIA, transient ischaemic attack.
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Survival of the fattestDM/IFG (HR for death per kg/m
2 increase in BMI 0.91,
95% CI 0.86 to 0.97; p¼0.003) but not in individuals
without DM/IFG (HR 1.01, 95% CI 0.95 to 1.07;
p¼0.811). These ﬁndings did not change noticeably
when excluding individuals with a BMI <20 or individ-
uals who died within 2-year follow-up. As shown in
table 2, the above relationship pattern between BMI and
all-cause mortality across DM/IFG status also applied to
cardiovascular mortality but not to non-cardiovascular
mortality.
After adjustment for sex, current smoking, diagnosed
hypertension, diagnosed angina pectoris, previous
myocardial infarction and previous stroke or TIA, the
decrease in death per kg/m
2 increase in BMI was 9% in
individuals with DM/IFG (HR 0.92, 95% CI 0.86 to 0.99;
p¼0.017).
Additionally, we performed a Cox PHREG analysis of
all participants using a model including, in addition to
categorised BMI (#25/>25) and DM/IFG status (no/
yes), the interaction between BMI and DM/IFG status. A
signiﬁcant negative interaction was found (log(HR)
 0.10, HR 0.90, 95% CI 0.83 to 0.99; p¼0.025).
Although not powered for it, some pertinent subgroup
analyses were performed. Thus, HR for death per kg/m
2
increase in BMI for individuals with known diabetes was
0.90 (95% CI 0.79 to 1.02; p¼0.102), for known or newly
detected diabetes 0.89 (95% CI 0.81 to 0.97; p¼0.008)
and for IFG alone 0.93 (95% CI 0.85 to 1.02; p¼0.136).
These HR were clearly lower than for individuals without
DM/IFG (HR 1.01).
BMI by time interaction was non-signiﬁcant (p¼0.328
for individuals with DM/IFG, p¼0.812 for individuals
without DM/IFG), suggesting that the proportional
hazard assumption was satisﬁed for BMI. The log( log
(cumulative survival)) curves for the DM/IFG status
categories (no/yes) were reasonably parallel, indicating
that the proportional hazard assumption was not
violated for DM/IFG status. Table 3 and ﬁgure 1 illus-
trate survival according to different combinations of
absence/presence of overweight/obesity and DM/IFG.
Among individuals with BMI #25 there was a conspic-
uous survival difference between those with and without
DM/IFG.
Cumulative survival according to different combina-
tions of absence/presence of overweight/obesity and
DM/IFG is illustrated by KaplaneMeier curves in
ﬁgure 2. Evidently, absence of overweight/obesity in
combination with DM/IFG delineates a subgroup with
a particularly poor prognosis. See table 3 for the results
of the corresponding Cox PHREG analyses.
DISCUSSION
The main ﬁnding of the present study was that, among
75-year-olds with DM/IFG, increased BMI is associated
Table 2 HRs and 95% CIs for all-cause mortality (if not otherwise stated) per 1 unit increase in BMI and FPG or versus
reference in individuals with and without DM/IFG
Variable
No DM/IFG (n[260) DM/IFG (n[172)
HR 95% CI p Value HR 95% CI p Value
BMI (kg/m
2) 1.01 0.95 to 1.07 0.811 0.91 0.86 to 0.97 0.003
BMI (kg/m
2), multi-adjusted* 1.01 0.94 to 1.08 0.770 0.92 0.86 to 0.99 0.017
BMI (kg/m
2), CV mortality 0.97 0.88 to 1.06 0.489 0.89 0.80 to 0.99 0.027
BMI (kg/m
2), non-CV mortality 1.04 0.97 to 1.12 0.259 1.03 0.94 to 1.14 0.533
BMI (kg/m
2), deaths within
2 year excluded (n¼420)
1.01 0.94 to 1.07 0.854 0.92 0.86 to 0.98 0.009
BMI (kg/m
2), subjects with
BMI <20 excluded (n¼410)
1.01 0.94 to 1.08 0.798 0.91 0.84 to 0.98 0.017
Overweight/obesity vs normal
weight (reference)
1.16 0.76 to 1.79 0.497 0.63 0.40 to 1.01 0.052
Obesity vs normal weight
(reference)
0.64 0.25 to 1.63 0.352 0.48 0.25 to 1.05 0.069
FPG (mmol/l) 1.00 0.55 to 1.80 0.986 1.10 1.01 to 1.19 0.026
*Adjusted for sex, current smoking, previously diagnosed hypertension, diagnosed angina pectoris, previous myocardial infarction and previous
stroke or transient ischaemic attack.
BMI, body mass index; CV, cardiovascular; DM, diabetes mellitus type 2; FPG, fasting plasma glucose; IFG, impaired fasting glucose.
Table 3 HRs and 95% CIs for all-cause mortality and
combinations of (BMI#25)/(BMI>25) and (No DM/IFG)/
(DM/IFG)
HR 95% CI p Value
(BMI#25)/(no
DM/IFG) (n¼134)
Reference¼1
(BMI#25)/
(DM/IFG) (n¼55)
2.2 1.4 to 3.5 0.001
(BMI>25)/(no
DM/IFG) (n¼127)
1.1 0.7 to 1.7 0.581
(BMI>25)/
(DM/IFG) (n¼116)
1.4 0.9 to 2.1 0.101
BMI, body mass index; CV, cardiovascular; DM, diabetes mellitus
type 2; FPG, fasting plasma glucose; IFG, impaired fasting
glucose.
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Survival of the fattestwith improved survival. This association remained
signiﬁcant when adjusting for prevalent cardiovascular
disease and cardiovascular risk factors. The above
unadjusted and adjusted associations did not change
noticeably when excluding individuals with a BMI <20
or individuals who died within 2-year follow-up. To our
knowledge, this is the ﬁrst reported study comparing the
association between mortality and BMI in elderly
subjects with and without DM/IFG. The mean fasting
blood glucose levels as well as the prevalence of DM/IFG
in the present cohort were very similar to the ﬁndings in
several European populations studied in the DECODE
project.
23 This suggests that the present cohort of
75-year-olds is representative of a general European
population.
The lack of a signiﬁcant association between mortality
and BMI within the cohort of 75-year-olds agrees with
current knowledge. Thus, among individuals aged
$70 years, only underweight and pronounced obesity
(BMI >35)
26 were associated with a signiﬁcantly higher
mortality risk relative to normal weight. A Japanese study
with an 11-year follow-up of 26747 Japanese subjects
aged 65e79 years demonstrated that lowest all-cause
mortality was found within a broad BMI range of
20.0e29.9.
27 Flicker et al
28 did not observe any greater
mortality among obese and overweight elderly subjects
in comparison to those with normal weight. In an
80-year-old community based Japanese population,
Takata et al
14 even observed decreased mortality among
obese individuals.
The obesity paradox
Our ﬁnding that obese hyperglycaemic individuals do
better than lean hyperglycaemic individuals is another
example of the so-called obesity paradox observed in
patients with certain diseases.
18e22 The obesity paradox
implies paradoxically decreased mortality and morbidity
in association with increasing BMI up to and including
obesity and has been reported among patients with severe
chronic diseases, for example renal insufﬁciency,
18
chronic obstructive pulmonary disease,
18 hypertension
21
and heart failure,
20 29 30 and in patients undergoing
percutaneous coronary interventions
19 31 32 and in those
with known coronary disease.
21 33e35 Advanced age is also
associated with the obesity paradox. The phenomenon
has been demonstrated in an 80-year-old community
based Japanese population by Takata et al.
14
It is unknown whether a low BMI is a marker of disease
severity or is harmful as such. Reverse causation implying
cachexia with a lowering of BMI caused by chron-
ic diseases has been proposed as an explanatory
mechanism for the obesity paradox.
18
Some recent research ﬁndings may be considered in
relation to the obesity paradox. Thus, studies of body
weight changes in healthy general populations over
5 years,
36 16 years
37 and 26 years
38 have demonstrated
that a decrease in body weight, even among those orig-
inally overweight/obese, was associated with increased
mortality compared to weight stability. In one of the
above studies, Strandberg et al
38 categorised 1114
healthy Finnish men (mean age 47) according to
whether their BMI was above or below 25 at baseline and
at re-examination after 26 years. Mortality during 7-year
follow-up was clearly highest in the group which had
Figure 1 Ten-year all-cause mortality categorised by body
mass index (BMI) (#25/>25) and diabetes mellitus type 2
(DM) or impaired fasting glucose (IFG) status (no/yes). The
proportion of non-survivors in the different categories are given
above each bar.
Figure 2 KaplaneMeier curves showing cumulative all-cause
mortality according to dichotomised body mass index (BMI)
(#25/>25) and diabetes mellitus type 2 (DM) or impaired
fasting glucose (IFG) status (no/yes). The numbers of
individuals at risk at 2, 4, 6 and 8 years were 420, 393, 357
and 328.
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Survival of the fattestchanged from overweight to normal weight and was
fairly equal between the other groups (log-rank test
between groups, p<0.001). The ﬁndings were robust for
adjustment for prevalent diseases at re-examination. The
mortality difference was due various causes, including
coronary artery disease, stroke and cancer.
It is not surprising that obvious chronic diseases cause
loss of body weight, but this Finnish study over 26 years
suggests a long cachectic process without the presence of
manifest chronic disease. Hypothetically, such a process
may be caused by, for example, slowly developing undi-
agnosed atherosclerosis. It is tempting to speculate that
the obesity paradox demonstrated in the present inves-
tigation among elderly subjects with DM/IFG may be
a consequence of such a ‘sub-cachectic’ process.
However, it must be noted that the consensus deﬁnition
of cachexia includes an inﬂammatory state
39 and the
present investigation provides no data on this topic.
It is noteworthy that the excess mortality among lean
individuals with DM/IFG in the present investigation
applies only to death from cardiovascular disease and
not from non-cardiovascular disease. This ﬁnding
suggests that atherosclerosis has a key role in the
sub-cachectic process supposed above.
Traditionally, BMI is regarded as a proxy for body fat.
In the present cohort a strong correlation between BMI
and waist circumference indicates that BMI closely
reﬂects abdominal fat mass. However, the volume of fat-
free mass also inﬂuences BMI. Physiologically, loss of
lean body mass, particularly muscle mass, occurs with
ageing
12 and sometimes leads to sarcopenia, charac-
terised by a marked decrease in muscle mass and muscle
strength.
18 40 In a Danish cohort of 50e64-years-olds, in
whom body composition was estimated by measuring
bioelectric impedance, both high body fat and low
fat-free mass were independent predictors of all-cause
mortality.
41 Similar results were reported by Heitmann
et al
42 among 60-year-old Swedish men.
Possible underlying mechanism
Modulation of the inﬂammatory response is a potential
mechanism underlying the obesity paradox. Differences
in the cytokine tumour necrosis factor-a (TNF-a) system
are observed between lean and obese patients with heart
failure.
29 43 Leaner patients with heart failure have been
shown to have increased levels of TNF-a and other
inﬂammatory cytokines compared with obese patients.
44
Furthermore, there is a large body of evidence that
inﬂammation is closely related to atherosclerosis,
45 but
there is no simple answer as to whether the immune
response promotes or retards atherogenesis.
46
Considering the obesity paradox in older people with
DM/IFG demonstrated in the present investigation, it is
noteworthy that several markers of inﬂammation
including white blood cell counts, C reactive protein and
interleukin-6 predict the development of DM
47 48 and
that cytokines such as TNF-a and interleukin-6 are raised
in individuals with DM.
49
Policy implications
The results from the present study do not necessarily
apply to intentional weight loss. For example, lean
subjects with diabetes may have lost weight because of
unrecognised cardiovascular complications related to
their disease. This does not exclude the possibility that
obese patients with diabetes may beneﬁt from inten-
tional weight loss. Nevertheless, as regards older people,
the present ﬁndings raise questions concerning the
current guideline recommendations
50 of weight loss “for
all overweight and obese individuals who have or are at
risk of diabetes”. These recommendations
50 are mainly
based on observations that “modest weight loss has been
shown to reduce insulin resistance”. Further research on
this clinically important topic is needed.
A general ﬁnding from the literature is that inten-
tional weight loss improves cardiovascular risk proﬁle
but the effect on mortality is not consistent.
51 Two
studies concerning older study populations (aged>60
years) found some survival beneﬁt from intentional
weight loss.
52 53
The present investigation demonstrates that lean older
people with DM or IFG constitute a high-risk group for
total and cardiovascular mortality. Consequently, they
deserve particular medical attention and the possibility
of undiagnosed chronic disease must be considered.
Screening for DM/IFG and intensiﬁed glycaemic control
of known DM and IFG are possible options. However, the
evidence from long-term studies in older adults
demonstrating a possible beneﬁt of glycaemic control
is scarce.
54 55
Funding The original cardiovascular health survey was supported by grants
from SparbanksstiftelsenNya and Va ¨stmanland’s Research Foundation Against
Cardiovascular Diseases. The authors are independent from the funders of the
original study.
Competing interests None.
Ethics approval The study was approved by the research ethics committee of
Uppsala University, Sweden.
Contributors GN and JO conceived and designed the study, performed the data
analyses and interpreted the results. GN wrote the ﬁrst draft of the manuscript.
PH contributed to the initial collection of the data and veriﬁed the medical
diagnoses. All authors critically reviewed the manuscript for important
intellectual content and approved the ﬁnal version of the paper. JO acts as
guarantor of the paper.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Statistical code and datasets are available from the
corresponding author at john.ohrvik@ki.se.
REFERENCES
1. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and
cause-speciﬁc mortality in 900 000 adults: collaborative analyses of
57 prospective studies. Lancet 2009;373:1083e96.
2. Hu G. Gender difference in all-cause and cardiovascular mortality
related to hyperglycaemia and newly-diagnosed diabetes.
Diabetologia 2003;46:608e17.
3. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart
disease associated with diabetes in men and women: meta-analysis
of 37 prospective cohort studies. BMJ 2006;332:73e8.
4. Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h
postchallenge plasma glucose concentrations to mortality: data from
the Baltimore Longitudinal Study of Aging with a critical review of the
literature. Diabetes Care 2005;28:2626e32.
6 Nilsson G, Hedberg P, O ¨hrvik J. BMJ Open 2011;1:e000012. doi:10.1136/bmjopen-2010-000012
Survival of the fattest5. World Health Organization. Deﬁnition and Diagnosis of Diabetes
Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF
Consultation. WHO Press, Geneva, 2006.
6. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood
glucose concentration, and risk of vascular disease: a collaborative
meta-analysis of 102 prospective studies. Lancet 2010;375:2215e22.
7. Alberti KG, Zimmet PZ. Deﬁnition, diagnosis and classiﬁcation of
diabetes mellitus and its complications. Part 1: diagnosis and
classiﬁcation of diabetes mellitus provisional report of a WHO
consultation. Diabet Med 1998;15:539e53.
8. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired
impaired fasting glusose to type 2 diabetes. Diabetes Care
2007;30:228e33.
9. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and
all-cause mortality in individuals with diabetes mellitus, impaired
fasting glucose, and impaired glucose tolerance: the Australian
Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation
2007;116:151e7.
10. Stevens J, Cai J, Pamuk ER, et al. The effect of age on the
association between body-mass index and mortality. N Engl J Med
1998;338:1e7.
11. Elia M. Obesity in the elderly. Obes Res 2001;9(Suppl 4):244Se8S.
12. Zamboni M, Mazzali G, Zoico E, et al. Health consequences of
obesity in the elderly: a review of four unresolved questions. Int J
Obes (Lond) 2005;29:1011e29.
13. Waaler HT. Height, weight and mortality. The Norwegian experience.
Acta Med Scand Suppl 1984;679:1e56.
14. Takata Y, Ansai T, Soh I, et al. Association between body mass index
and mortality in an 80-year-old population. J Am Geriatr Soc
2007;55:913e17.
15. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment
of federal guidelines for overweight and obesity as they apply to
elderly persons. Arch Intern Med 2001;161:1194e203.
16. Gu K, Cowie CC, Harris MI. Mortality in adults with and without
diabetes in a national cohort of the U.S. population, 1971e1993.
Diabetes Care 1998;21:1138e45.
17. Berger B, Stenstrom G, Sundkvist G. Incidence, prevalence, and
mortality of diabetes in a large population. A report from the
Skaraborg Diabetes Registry. Diabetes Care 1999;22:773e8.
18. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, et al. Curr Opin Clin
Nutr Metab Care 2007;10:433e42.
19. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity
on the short-term and long-term outcomes after percutaneous
coronary intervention: the obesity paradox? J Am Coll Cardiol
2002;39:578e84.
20. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass
index and outcomes in patients with heart failure. Arch Intern Med
2005;165:55e61.
21. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in
patients with hypertension and coronary artery disease. Am J Med
2007;120:863e70.
22. Andreotti F, Rio T, Lavorgna A. Body fat and cardiovascular risk:
understanding the obesity paradox. Eur Heart J 2009;30:752e4.
23. DECODE Study Group. Age- and sex-speciﬁc prevalences of
diabetes and impaired glucose regulation in 13 European cohorts.
Diabetes Care 2003;26:61e9.
24. American Diabetes Association. Diagnosis and classiﬁcation of
diabetes mellitus. Diabetes Care 2004;27(Suppl 1):S5e10.
25. World Health Organization. Obesity. Preventing and managing the
global epidemic. Report of a WHO consultation on obesity. WHO/
NUT/NCD/981, WHO, Geneva. 1998.
26. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths
associated with underweight, overweight, and obesity. JAMA
2005;293:1861e7.
27. Tamakoshi A, Yatsuya H, Lin Y, et al. BMI and all-cause mortality
among Japanese older adults: ﬁndings from the Japan collaborative
cohort study. Obesity (Silver Spring) 2010;18:362e9.
28. Flicker L, McCaul KA, Hankey GJ, et al. Body mass index and survival
in men and women aged 70 to 75. J Am Geriatr Soc 2010;58:234e41.
29. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship
between obesity and mortality in patients with heart failure. J Am Coll
Cardiol 2001;38:789e95.
30. Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index
and mortality in heart failure: a meta-analysis. Am Heart J
2008;156:13e22.
31. Cox N, Resnic FS, Popma JJ, et al. Comparison of the risk of
vascular complications associated with femoral and radial access
coronary catheterization procedures in obese versus nonobese
patients. Am J Cardiol 2004;94:1174e7.
32. Gurm HS, Brennan DM, Booth J, et al. Impact of body mass index on
outcome after percutaneous coronary intervention (the obesity
paradox). Am J Cardiol 2002;90:42e5.
33. Romero-Corral A, Montori VM, Somers VK, et al. Association of
bodyweight with total mortality and with cardiovascular events in
coronary artery disease: a systematic review of cohort studies.
Lancet 2006;368:666e78.
34. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and
mortality in a large prospective cohort of persons 50 to 71 years old.
N Engl J Med 2006;355:763e78.
35. Kang X, Shaw LJ, Hayes SW, et al. Impact of body mass index on
cardiac mortality in patients with known or suspected coronary artery
disease undergoing myocardial perfusion single-photon emission
computed tomography. J Am Coll Cardiol 2006;47:1418e26.
36. Nanri A, Mizoue T, Takahashi Y, et al. Weight change and all-cause,
cancer and cardiovascular disease mortality in Japanese men and
women: the Japan Public Health Center-Based Prospective Study.
Int J Obes (Lond) 2010;34:348e56.
37. Nilsson PM, Nilsson JA, Hedblad B, et al. The enigma of increased
non-cancer mortality after weight loss in healthy men who are
overweight or obese. J Intern Med 2002;252:70e8.
38. Strandberg TE, Strandberg AY, Salomaa VV, et al. Explaining
the obesity paradox: cardiovascular risk, weight change, and
mortality during long-term follow-up in men. Eur Heart J
2009;30:1720e7.
39. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new deﬁnition.
Clin Nutr 2008;27:793e9.
40. Muscaritoli M, Anker SD, Argiles J, et al. Consensus deﬁnition of
sarcopenia, cachexia and pre-cachexia: Joint document elaborated
by Special Interest Groups (SIG) “cachexia-anorexia in chronic
wasting diseases” and “nutrition in geriatrics”. Clin Nutr
2010;29:154e9.
41. Bigaard J, Frederiksen K, Tjonneland A, et al. Body fat and fat-free
mass and all-cause mortality. Obes Res 2004;12:1042e9.
42. Heitmann BL, Erikson H, Ellsinger BM, et al. Mortality associated with
body fat, fat-free mass and body mass index among 60-year-old
swedish men-a 22-year follow-up. The study of men born in 1913.
Int J Obes Relat Metab Disord 2000;24:33e7.
43. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble
tumor necrosis factor receptors by human subcutaneous adipose
tissue in vivo. Am J Physiol 1999;277:E971e5.
44. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis
factor in the pathophysiology of heart failure. J Am Coll Cardiol
2000;35:537e44.
45. Libby P, Ridker PM, Maseri A. Inﬂammation and atherosclerosis.
Circulation 2002;105:1135e43.
46. Hansson GK, Libby P. The immune response in atherosclerosis:
a double-edged sword. Nat Rev Immunol 2006;6:508e19.
47. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of
inﬂammation and prediction of diabetes mellitus in adults
(Atherosclerosis Risk in Communities study): a cohort study.
Lancet 1999;353:1649e52.
48. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin
6, and risk of developing type 2 diabetes mellitus. JAMA
2001;286:327e34.
49. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of
the innate immune system: association of acute-phase reactants and
interleukin-6 with metabolic syndrome X. Diabetologia
1997;40:1286e92.
50. American Diabetes Association. Standards of medical care in
diabetesd2010. Diabetes Care 2010;33(Suppl 1):S11e61.
51. Simonsen MK, Hundrup YA, Obel EB, et al. Intentional weight loss
and mortality among initially healthy men and women. Nutr Rev
2008;66:375e86.
52. French SA, Folsom AR, Jeffery RW, et al. Prospective study of
intentionality of weight loss and mortality in older women: the Iowa
Women’s Health Study. Am J Epidemiol 1999;149:504e14.
53. Wannamethee SG, Shaper AG, Lennon L. Reasons for intentional
weight loss, unintentional weight loss, and mortality in older men.
Arch Intern Med 2005;165:1035e40.
54. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the
care of the older person with diabetes mellitus. J Am Geriatr Soc
2003;51(5 Suppl Guidelines):S265e80.
55. American Diabetes Association. Standards of medical care in
diabetesd2008. Diabetes Care 2008;31:(Suppl 1):S12e54.
Nilsson G, Hedberg P, O ¨hrvik J. BMJ Open 2011;1:e000012. doi:10.1136/bmjopen-2010-000012 7
Survival of the fattest